Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents

Current Medicinal Chemistry

Volumn 19, Issue 34, 2012, Pages 5885-5894

  Shan, Yuanyuan ^a   Ma, Ying ^a   Wang, Maoyi ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti influenza agents; Computer aided drug design; Neuraminidase (NA); Resistance

Indexed keywords

INFLUENZA VACCINE; LANINAMIVIR; NATURAL PRODUCT; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIVIRAL RESISTANCE; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG STRUCTURE; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; REVIEW; UPPER RESPIRATORY TRACT; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROTEIN STRUCTURE, TERTIARY;

EID: 84871339523     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804143358     Document Type: Review

References (85)

1. Seibert, C. W.; Rahmat, S.; Krammer, F.; Palese, P.; Bouvier, N. M. Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance. J Virol, 2012, 86(9), 5386-5389.
2. Moscona, A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005, 353(13), 1363-1373.
3. Trakulsrichai, S.; Watcharananan, S. P.; Chantratita, W. Influenza A (H1N1) 2009 reinfection in Thailand. J Infect Public Health. 2012, 5(2):211-4.
4. Li, K. S.; Guan, Y.; Wang, J.; Smith, G. J.; Xu, K. M.; Duan, L.; Rahardjo, A. P.; Puthavathana, P.; Buranathai' C.; Nguyen, T. D.; Estoepangestie, A. T.; Chaisingh, A.; Auewarakul, P.; Long, H. T.; Hanh, N. T.; Webby, R. J.; Poon, L. L.; Chen, H.; Shortridge, K. F.; Yuen, K. Y.; Webster, R. G.; Peiris, J. S. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004, 430(6996), 209-213.
5. Libster, R.; Bugna, J.; Coviello, S.; Hijano, D. R.; Dunaiewsky, M.; Reynoso, N.; Cavalieri, M. L.; Guglielmo, M. C.; Areso, M. S.; Gilligan, T.; Santucho, F.; Cabral, G.; Gregorio, G. L.; Moreno, R.; Lutz, M. I.; Panigasi, A. L.; Saligari, L.; Caballero, M. T.; Egües Almeida, R. M.; Gutierrez Meyer, M. E.; Neder, M. D.; Davenport, M. C.; Del Valle M. P.; Santidrian, V. S.; Mosca, G.; Garcia Domínguez, M.; Alvarez, L.; Landa, P.; Pota, A.; Boloñati, N.; Dalamon, R.; Sanchez Mercol, V. I.; Espinoza, M.; Peuchot, J. C.; Karolinski, A.; Bruno, M.; Borsa, A.; Ferrero, F.; Bonina, A.; Ramonet, M.; Albano, L. C.; Luedicke, N.; Alterman, E.; Savy, V.; Baumeister, E.; Chappell, J. D.; Edwards, K. M.; Melendi, G. A.; Polack, F. P. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med. 2010, 362(1), 45-55.
6. Wu, S.; Metcalf, J. P.; Wu, W. Innate immune response to influenza virus. Curr Opin Infect Dis. 2011, 24(3), 235-40.
7. Veit, M.; Thaa, B. Association of influenza virus proteins with membrane rafts. Adv Virol. 2011, doi:10.1155/2011/370606.
8. Skehel, J. J.; Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000, 69(1), 531-569.
9. Garman, E.; Laver, G. Controlling influenza by inhibiting the virus's neuraminidase. Curr Drug Targets. 2004, 5(2), 119-136.
10. Liu, A. L.; Wang, Y. T.; Du, G. H. Neuraminidase as a target for drugs for the treatment of influenza. Drugs Future. 2005, 30(8), 799-806.
11. Block, S. L.; Yi, T.; Sheldon, E.; Dubovsky, F.; Falloon, J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011, 29(50), 9391-9397.
12. Magano, J. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chem Rev. 2009, 109(9), 4398-4438.
13. Dreitlein, W. B.; Maratos, J.; Brocavich, J. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin Ther. 2001, 23(3), 327-355.
14. Grantham, M. L.; Stewart, S. M.; Lalime, E. N.; Pekosz, A. Tyrosines in the influenza A virus M2 protein cytoplasmic tail are critical for production of infectious virus particles. J Virol. 2010, 84(17), 8765-8776.
15. Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993, 363(6428), 418-423.
16. Ryan, D. M.; Ticehurst, J.; Dempsey, M. H.; Penn, C. R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994, 38(10), 2270-2275.
17. Carr, J.; Ives, J.; Kelly, L.; Lambkin, R.; Oxford, J.; Mendel, D.; Tai, L.; Roberts, N. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002, 54(2):79-88.
18. Shetty, A. K.; Peek, L. A. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther. 2012, 10(2), 123-143.
19. Ikematsu, H.; Kawai, N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011, 9(10), 851-8577.
20. Piao, F.; Hong, J. H. Design and synthesis of a cyclopentene scaffold mimicking oseltamivir as a novel neuraminidase inhibitor. Bull. Korean Chem. Soc. 2008, 29(11), 2221-2226.
21. Krueger, A. C.; Xu, Y.; Kati, W. M.; Kempf, D. J.; Maring, C. J.; McDaniel, K. F.; Molla, A.; Montgomery, D.; Kohlbrenner, W. E. Synthesis of potent pyrrolidine influenza neuraminidase inhibitors. Bioorg Med Chem Lett. 2008, 18(5), 1692-1695.
22. Zhang, J.; Wang, Q.; Fang, H.; Xu, W.; Liu, A.; Du, G. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. Bioorg Med Chem. 2008, 16(7), 3839-3847.
23. Weiwer, M.; Chen, C. C.; Kemp, M. M.; Linhardt, R. J. Synthesis and Biological Evaluation of Non-Hydrolyzable 1, 2, 3-Triazole-Linked Sialic Acid Derivatives as Neuraminidase Inhibitors. Eur. J. Org. Chem. 2009, 2009(16):2611-2620.
24. Sakamoto, J.; Koyama, T.; Miyamoto, D.; Yingsakmongkon, S.; Hidari, K. I.; Jampangern, W.; Suzuki, T.; Suzuki, Y.; Esumi, Y; Nakamura, T.; Hatano, K.; Terunuma, D.; Matsuoka, K. Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties. Bioorg Med Chem. 2009, 17(15), 5451-5464.
25. Mohan, S.; McAtamney, S.; Haselhorst, T.; von Itzstein, M.; Pinto, B. M. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J Med Chem. 2010, 53(20), 7377-7391.
26. Bromba, C. M.; Mason, J. W.; Brant, M. G.; Chan, T.; Lunke, M. D.; Petric, M.; Boulanger, M. J.; Wulff, J. E. The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase. Bioorg Med Chem Lett. 2011, 21(23), 7137-7141.
27. Xiong, R. S.; Zhao, Q. J.; Zhu, H. H.; Liu, Z.; Wei, Y. B.; Shen, J. S. Synthesis of novel analogs of Zanamivir as neuraminidase inhibitors. Chin Chem Lett. 2010, 21(11), 1338-1341.
28. Albohy, A.; Mohan, S.; Zheng, R. B.; Pinto, B. M.; Cairo CW. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes. Bioorg Med Chem. 2011, 19(9), 2817-2822.
29. Liu, Y.; Jing, F.; Xu, Y.; Xie, Y.; Shi, F.; Fang, H.; Li, M.; Xu, W. Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. Bioorg Med Chem. 2011, 19(7), 2342-2348.
30. Nishino, R.; Ikeda, K.; Hayakawa, T; Takahashi, T.; Suzuki, T.; Sato, M. Syntheses of 2-deoxy-2, 3-didehydro-N-acetylneuraminic acid analogs modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1. Bioorg Med Chem. 2011, 19(7), 2418-2427.
31. Suzuki, K.; Koyama, T.; Yingsakmongkon, S.; Suzuki, Y.; Hatano, K.; Matsuoka, K. Synthesis and biological evaluation of sialic acid derivatives containing a long hydrophobic chain at the anomeric position and their C-5 linked polymers as potent influenza virus inhibitors. Bioorg Med Chem. 2012, 20(1), 446-454.
32. Kongkamnerd, J.; Cappelletti, L.; Prandi, A.; Seneci, P.; Rungrotmongkol, T.; Jongaroonngamsang, N.; Rojsitthisak, P.; Frecer, V.; Milani, A.; Cattoli, G.; Terregino, C.; Capua, I.; Beneduce, L.; Gallotta, A.; Pengo, P.; Fassina, G.; Miertus, S.; De-Eknamkul, W. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. Bioorg Med Chem. 2012, 20(6), 2152-2157.
33. Grienke, U.; Schmidtke, M.; von Grafenstein, S.; Kirchmair, J.; Liedl, K. R.; Rollinger, J. M. Influenza neuraminidase: a druggable target for natural products. Nat Prod Rep. 2012, 29(1), 11-36.
34. McChesney, J. D.; Venkataraman, S. K.; Henri, J. T. Plant natural products: back to the future or into extinction? Phytochemistry. 2007, 68(14), 2015-2022.
35. Liu, A. L.; Wang, H. D.; Lee, S. M.; Wang, Y. T; Du, G. H. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem. 2008, 16(15), 7141-7147.
36. Liu, A. L.; Liu, B.; Qin, H. L.; Lee, S. M.; Wang, Y. T.; Du, G. H. Antiinfluenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa. Planta Med. 2008, 74(8), 847-851.
37. Ryu, Y. B.; Curtis-Long, M. J.; Kim, J. H.; Jeong, S. H.; Yang, M. S.; Lee, K. W.; Lee, W. S.; Park, K. H. Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition. ioorg Med Chem Lett. 2008, 18(23), 6046-6049.
38. Park, J. Y.; Jeong, H. J.; Kim, Y. M.; Park, S. J.; Rho, M. C.; Park, K. H.; Ryu, Y. B.; Lee, W. S. Characteristic of alkylated chalcones from Angelica keiskei on influenza virus neuraminidase inhibition. Bioorg Med Chem Lett. 2011, 21(18), 5602-5604.
39. Jeong, H. J.; Ryu, Y. B.; Park, S. J.; Kim, J. H,.; Kwon, H. J.; Kim, J. H.; Park, K. H.; Rho, M. C.; Lee, W. S. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009, 17(19), 6816-6823.
40. Nguyen, P. H.; Nguyen, T. N.; Kang, K. W.; Ndinteh, D. T.; Mbafor, J. T.; Kim, Y. R.; Oh, W. K. Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010, 18(9), 3335-3344.
41. Dao, T. T.; Nguyen, P. H.; Lee, H. S.; Kim, E.; Park, J.; Lim, S. I.; Oh, W. K.; Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg Med Chem Lett. 2011, 21(1), 294-298.
42. Li, J.; Zhang, D.; Zhu, X.; He, Z.; Liu, S.; Li, M.; Pang, J.; Lin, Y. Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase. Mar. Drugs. 2011, 9(10), 1887-1901.
43. Xu, H.; Jiang, N.; Guo Y, Jiao, R. H.; Cui, J. T.; Song, Y. C.; Tan, R. X. Fully substituted unsaturated lactones from endophytic Myrothecium sp. J Asian Nat Prod Res. 2011, 13(11), 1003-1007.
44. Luo, H. J.; Wang, J. Z.; Chen, J. F.; Zou, K. Docking study on chlorogenic acid as a potential H5N1 influenza A virus neuraminidase inhibitor. Med Chem Res. 2011, 20(5), 554-557.
45. Nguyen, T N A.; Dao, T. T.; Tung, B. T.; Choi, H.; Kim, E.; Park, J.; Lim, S. I.; Oh, W. K. Influenza A (H1N1) neuraminidase inhibitors from Vitis amurensis. Food Chem. 2011, 124(2), 437-443.
46. Woo, H. S.; Kim, D. W.; Curtis-Long, M. J.; Lee, B. W.; Lee, J. H.; Kim, J. Y.; Kang, J. E.; Park, K. H. Potent inhibition of bacterial neuraminidase activity by pterocarpans isolated from the roots of Lespedeza bicolor. Bioorg Med Chem Lett. 2011, 21(20), 6100-6103.
47. Upadhyay, A.; Chompoo, J.; Kishimoto, W.; Makise, T.; Tawata, S. HIV-1 integrase and neuraminidase inhibitors from Alpinia zerumbet. J Agric Food Chem. 2011, 59(7), 2857-2862.
48. Upadhyay, A.; Chompoo, J.; Taira, N.; Fukuta, M.; Gima, S.; Tawata, S. Solid-phase synthesis of mimosine tetrapeptides and their inhibitory activities on neuraminidase and tyrosinase. J Agric Food Chem. 2011, 59(24), 12858-12863.
49. Liu, S.; Yan, J.; Xing, J.; Song, F.; Liu, Z.; Liu, S. Characterization of compounds and potential neuraminidase inhibitors from the n-butanol extract of Compound Indigowoad Root Granule using ultrafiltration and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012, 59:96-101
50. Dao, T. T.; Nguyen, P. H.; Won, H. K.; Kim, E. H.; Park, J.; Won, B. Y.; Oh, W. K. Curcuminoids from Curcuma longa and their inhibitoryactivities on influenzaA neuraminidases. Food Chem. 2012, 134(1), 21-28.
51. Zhang, J.; Shan, Y.; Pan, X.; Wang, C.; Xu, W.; He, L. Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors. Chem Biol Drug Des. 2011, 78(4), 709-717.
52. Zhang. J.; Pan, X.; Wang, C.; Wang, F.; Li, P.; Xu, W.; He, L. Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors. Chem Biol Drug Des. 2012, 79(3), 353-359.
53. Lü, W. J.; Chen, Y. L.; Ma, W. P.; Zhang, X. Y,; Luan, F.; Liu, M. C.; Chen, X. G.; Hu, Z. D. QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network. Eur J Med Chem. 2008, 43(3), 569-576.
54. Nair, P. C.; Sobhia, M. E. Quantitative structure activity relationship studies on thiourea analogs as influenza virus neuraminidase inhibitors. Eur J Med Chem. 2008, 43(2), 293-299.
55. García-Sosa, A. T.; Sild, S.; Maran, U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model. 2008, 48(10), 2074-2080.
56. D'Souza, C.; Kanyalkar, M.; Joshi, M.; Coutinho, E. Srivastava S. Search for novel neuraminidase inhibitors: Design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods. Biochim Biophys Acta. 2009, 1788(9), 1740-1751.
57. Li, Z. S.; Sun, J. Y.; Liang, G. Z.; Lu, F. L.; Zhu, W. P.; Zhang, M. J.; Zhang, Y.; Yang, S. B.; Shu, M.; Chen, G. H.; Lu, T. T. On three-dimensional holographic vector of atomic interaction field analysis for influenza neuraminidase inhibitors. Chem Biol Drug Des. 2009, 73(2), 236-243.
58. Abu Hammad, A. M.; Taha, M. O. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J Chem Inf Model. 2009, 49(4), 978-996.
59. An, J.; Lee, D. C.; Law, A. H.; Yang, C. L.; Poon, L. L.; Lau, A. S.; Jones, S. J. A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. J Med Chem. 2009, 52(9), 2667-2672.
60. Park, J. W.; Jo, W. H. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Eur J Med Chem. 2010, 45(2), 536-541.
61. Sun, J.; Cai, S.; Yan, N.; Mei, H. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Eur J Med Chem. 2010, 45(3), 1008-1014.
62. Yang, Z.; Yang, G.; Zu, Y.; Fu, Y.; Zhou, L. Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors. Int J Mol Sci. 2010, 11(12), 4932-4951.
63. Wang, Y. T.; Chan, C. H.; Su, Z. Y.; Chen, C. L. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A (H1N1) influenza neuraminidase. Biophys Chem. 2010, 147(1-2), 74-80.
64. Durrant, J. D.; McCammon, J. A. Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Comput Biol Chem. 2010, 34(2), 97-105.
65. Mercader, A. G.; Pomilio, A. B. QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors. Eur J Med Chem. 2010, 45(5), 1724-1730.
66. Murumkar, P. R..; Le, L.; Truong, T. N.; Yadav, M. R. Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling. Med Chem Commun. 2011, 2(8), 710-719.
67. Chavan, S.; Bhayye, S.; Sobhia, M. E. Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors. Mol Divers. 2011, 15(4), 979-987.
68. Gao, L.; Zu, M.; Wu, S.; Liu, A. L.; Du, G. H. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase. Bioorg Med Chem Lett. 2011, 21(19), 5964-5970.
69. Kirchmair, J.; Rollinger, J. M.; Liedl, K. R.; Seidel, N.; Krumbholz, A.; Schmidtke, M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med Chem. 2011, 3(4), 437-450.
70. Wang, Y.; Wu, D.; Yu, D.; Wang, Z.; Tian, L.; Wang, Y.; Han, W.; Fang, X. Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase. J Mol Model. 2012, DOI 10.1007/s00894-011-1349-0.
71. Ison, M. G. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011, 1(6), 563-573.
72. Xie, Y.; Gong, J.; Li, M.; Fang, H.; Xu, W. The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase. Curr Med Chem. 2011, 18(7), 1050-1066.
73. Ilyushina, N. A.; Seiler, J. P.; Rehg, J. E.; Webster, R. G.; Govorkova, E. A. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 2010, 6(5), e1000933.
74. Oakley, A. J.; Barrett, S.; Peat, T. S.; Newman, J.; Streltsov, V. A.; Waddington, L.; Saito, T.; Tashiro, M.; McKimm-Breschkin, J. L. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem. 2010, 53(17), 6421-6431.
75. Van der Vries E.; Schutten, M.; Boucher, C. A. The potential for multidrugresistant influenza. Curr Opin Infect Dis. 2011, 24(6), 599-604.
76. Tamura, D.; Sugaya, N.; Ozawa, M.; Takano, R.; Ichikawa, M,.; Yamazaki, M.; Kawakami, C.; Shimizu, H.; Uehara, R.; Kiso, M.; Kawakami, E.; Mitamura, K.; Kawaoka, Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011, 52(4), 432-437.
77. Thorlund, K.; Awad, T.; Boivin, G.; Thabane, L Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011, 11:134-147.
78. Karthick, V.; Shanthi, V.; Rajasekaran, R.; Ramanathan, K. In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir. Protoplasma. 2012, DOI 10.1007/s00709-012-0394-6.
79. Mihajlovic, M. L.; Mitrasinovic, P. M. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem. 2008, 136(2-3):152-158.
80. Govorkova, E. A.; Leneva, I. A.; Goloubeva, O. G.; Bush, K.; Webster, R. G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother. 2001, 45(10):2723-2732.
81. Roberts, N. A.; Govorkova, E. A. The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses. In: Global view of the fight against influenza, Mitrasinovic, P. M. Ed.; New York, Nova Science Publishers Inc 2009;93-118.
82. Mitrasinovic, P. M. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets. 2010, 11(3):315-326.
83. Mitrasinovic, P. M. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem. 2009, 140(1-3):35-38.
84. Mihajlovic, M. L.; Mitrasinovic, P. M. Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs). Mol Simul. 2009, 35(4):311-324.
85. Mihajlovic, M. L.; Mitrasinovic, P. M. Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study. J. Serb. Chem. Soc. 2009, 74(1):1-13.